Insulet is a medical technology company that makes a tubeless, wearable insulin pump called the Omnipod. The company reached $2.71 billion in revenue in 2025, growing 31% over the prior year as more patients switched from traditional injections to its automated system. In 2024, the business passed a major milestone by generating over $2 billion in annual revenue for the first time.
The investment thesis on Insulet is that its tubeless "patch pump" design is winning a massive shift in how diabetes is managed, and it is now moving into the much larger type 2 market. While competitors still rely on tubed pumps that can be bulky and restrictive, Insulet’s pod is a simple, disposable patch that users control with a smartphone. This convenience advantage is difficult to replicate because of the specialized manufacturing scale required to keep the disposable pods cheap.
We think Insulet is one of the highest-quality growth stories in healthcare, and the current price does not reflect how much the type 2 market could expand the business. The primary risk is a competitor launching a similar tubeless device, but Insulet has a multi-year lead in both clinical data and manufacturing scale.
Insulet's stock price has crashed over the last few years and is down about half from where it started five years ago. While the company makes a popular wearable insulin pump that more patients are using, the stock took a hit from product recalls and a lost court case over its technology.
What does it do?
Insulet is a growth-stage business that earns money by selling a proprietary, tubeless insulin delivery system called Omnipod. Instead of a traditional pump that connects to the body with a plastic tube, the Omnipod is a small, waterproof "pod" that sticks directly to the skin like a patch. Customers buy a starter kit and then purchase ongoing supplies of disposable pods, which they replace every three days. This creates a razor-and-blade model where the company makes most of its money from recurring sales of the pods themselves. Most patients get their pods through the pharmacy, making it as easy to pick up as a prescription.
Where does revenue come from?
Almost all revenue comes from the sale of Omnipod systems to patients with insulin-dependent diabetes. The Omnipod product line accounts for over 99% of total company revenue. This is split into U.S. Omnipod sales, which grew 28% in the most recent quarter, and International Omnipod sales, which surged by 59%. A tiny remainder of revenue comes from a drug delivery unit that adapts the pod technology for other injectable medications.
Revenue Breakdown
Revenue by Geography
Who are its customers?
Insulet serves hundreds of thousands of people with insulin-dependent diabetes, with U.S. Omnipod revenue reaching $515.6 million in the latest quarter. The customer base is split between patients with Type 1 diabetes and a rapidly growing segment of patients with Type 2 diabetes. In the first quarter of 2026, international revenue grew to $242.9 million as the company expanded into 19 countries. Most customers are "Podders" who have switched from multiple daily injections because the automated system reduces the constant burden of managing blood sugar. The company does not disclose a precise total user count in its press releases, but its $2.71 billion in annual revenue reflects a massive, global recurring user base.
What gives it staying power?
Insulet has staying power because patients rarely switch once they start on a specific pump system. Moving to a new system requires learning new software and often a new prescription from a doctor. This creates high switching costs that protect Insulet’s revenue once a patient joins the "Podder" community.
Where is it headed?
Insulet is making a massive strategic bet on the Type 2 diabetes market. While pumps were traditionally for Type 1 patients, the company is now running pivotal trials like the EVOLVE study to gain formal clearance for Type 2 adults. This would open a market three times larger than its current one, transforming the company from a niche player into a mainstream healthcare giant.
The single most important trend is that Insulet is consistently growing revenue by over 20%, even as the business gets larger. Revenue grew 33.9% to $761.7 million in the most recent quarter, proving that the move toward automated insulin delivery is still accelerating. This growth is being driven by the successful launch of Omnipod 5 across global markets.
Cash quality is high because the company has turned its once-negative cash flow into a reliable $380 million annual engine. Free cash flow more than quintupled from $70 million in 2023 to $380 million in 2025. This allows the company to fund its own manufacturing expansions and share buybacks without needing to take on more debt.
The balance sheet is in a strong position with a manageable debt-to-equity ratio of 0.73x. This level of debt is modest for a company with such high recurring revenue and $122 million in quarterly operating income. It gives management the flexibility to invest in new automated manufacturing lines in Malaysia and the U.S. to lower the cost of each pod.
Insulet is a financially exceptional business that has combined high growth with consistent margin expansion and reliable cash generation.
International growth is exploding, with revenue outside the U.S. rising 59% in the latest quarter. This growth is being fueled by the rollout of Omnipod 5 into 19 countries, including a recent launch in the Middle East. As the company reaches more markets, it reduces its reliance on the U.S. healthcare system alone.
Competition from tubed pump makers like Tandem and Medtronic could intensify if they launch their own tubeless versions. If a major competitor successfully replicates the "patch pump" design, it could pressure Insulet's 71% gross margins. Management is defending this risk by integrating its system with more glucose sensors like the FreeStyle Libre 3 Plus.
The insulin delivery market is roughly $15 billion today and is growing about 15% annually as patients move away from manual injections toward automated pumps. This market is on track to exceed $30 billion by 2030 as technology becomes simpler and insurance coverage expands. Pricing power is strong because these are life-critical devices with high regulatory hurdles that prevent cheap generic competition. Insulet is a leader in this market, specifically dominating the "tubeless" segment where it currently faces no direct, large-scale competitor.
The insulin pump market is rationally structured with only a few major players because the clinical and regulatory barriers to entry are extremely high. Companies compete on the quality of their automated algorithms and the convenience of their hardware. One sentence: this dynamic protects long-term pricing power as patients prioritize reliable technology over the lowest price.
Tandem and Medtronic are the primary competitors, but they mostly sell tubed pumps that require a plastic line running from the device to the body. Their attack vector is integrating their pumps more tightly with their own sensors or better software algorithms. Tandem is the most dangerous threat because it has a loyal user base and is actively trying to develop its own tubeless "patch" system.
Insulet is clearly gaining share, as shown by its 33.9% revenue growth which is significantly higher than the overall market. This growth proves that the "tubeless" design is the preferred choice for new patients starting pump therapy.
The primary source of protection is high switching costs combined with proprietary manufacturing IP. Once a patient starts on the Omnipod, they are trained on its specific software and their doctor writes a prescription for the ongoing pods. Switching to a competitor requires a new doctor's visit and retraining, which keeps retention high and generates 71% gross margins.
The 16.4% ROIC and 71% gross margins prove that Insulet has a real structural advantage. These numbers have stayed high even as the company scaled past $2 billion in revenue, which is not typical for a business without a moat. The combination of high margins and high retention proves that the convenience of the tubeless design creates a wide competitive gap.
The moat is widening as Insulet integrates with more glucose sensors and builds out massive, automated manufacturing lines that competitors cannot easily match.
Delivered 9 consecutive years of 20% or more constant currency revenue growth.
Repurchased 1.25 million shares in Q1 2026 while funding global manufacturing expansion.
CEO Ashley McEvoy leads a team that has consistently beaten revenue guidance for years.
Capital Allocation Track Record
Ashley McEvoy and her team have demonstrated exceptional leadership by maintaining high-double-digit growth for nearly a decade. They have successfully navigated the transition from a hardware-only company to an automated insulin delivery (AID) leader with the launch of Omnipod 5. Their strategic judgment is evidenced by the decision to move the pod delivery into the pharmacy channel, which significantly lowered the barrier for new patients to start the therapy compared to traditional durable medical equipment.
There is minimal key-person risk as the company has built a deep bench of medical device veterans and has a clear succession plan. The board is independent, and the company’s incentives are closely tied to constant currency revenue growth and operating margin expansion. While the company is scaling rapidly, the governance structure is mature, and the management team has a high degree of credibility with both physicians and investors.
We expect revenue to grow from $3.3B in FY2026 to $7.2B in FY2031 (~17% CAGR), with EPS growing from $6.48 to $17.37 (~22% CAGR). More patients are switching from manual injections to the Omnipod 5 automated system, especially as the product enters the large type 2 diabetes market. The cost of making each disposable pod drops as production volume increases, allowing more profit to be captured from every sale. EPS grows faster than revenue because profit margins are expanding while the company keeps its corporate overhead relatively stable. Operating margin expected to reach ~28% by FY2031.
Expansion into the massive Type 2 diabetes market. Gaining FDA clearance for Type 2 would triple the number of potential customers and accelerate revenue growth.
Integration with multiple continuous glucose monitors. Adding connectivity to sensors like FreeStyle Libre 3 Plus makes Omnipod 5 attractive to a broader patient base.
Manufacturing scale lowers pod unit costs. High-volume automation in Malaysia and the U.S. should drive gross margins toward 75% as fixed costs are spread.
Competitors launch high-quality tubeless patch pumps. If Tandem or a new entrant launches a successful tubeless device, Insulet's 99% market share in this niche will erode.
Changes in pharmacy reimbursement for medical devices. Any shift in how insurance companies pay for pods in the pharmacy channel could hurt patient access and margins.
Slower than expected adoption in Type 2 patients. Type 2 patients may be more resistant to wearing a device than Type 1 patients, potentially limiting the growth runway.
Below is our estimate of current and future fair value, with detailed reasoning and assumptions. Fair value is a judgment, not a fact, and other analysts will likely land on different numbers. Use it as one data point in your research, and apply your own discretion in any investing decision.
We use a Forward P/E approach (price-to-earnings applied to next year's earnings) as the primary valuation framework. It fits Insulet because the company is consistently GAAP (Generally Accepted Accounting Principles) profitable and possesses a highly predictable, subscription-like recurring revenue model through its consumable "Pods" that patients replace every three days.
Applying a 35x multiple to our FY2027 EPS estimate of $8.11 results in a fair value of $284 per share. A 35x multiple sits at the mid-point of the high-growth medical technology range of 25x to 45x—specifically between slower-growing Medtronic (18x) and the high-growth peer DexCom (38x)—which is justified by Insulet's superior 30% plus revenue growth profile and its current "Wide Moat" status. The $8.11 EPS base is taken directly from the deterministic projection for the first full fiscal year following the current period.
A 5-year Discounted Cash Flow (DCF) cross-check produces a fair value of $351, which is approximately 23% higher than our Forward P/E answer, confirming our valuation is conservative. Using a 10% discount rate and a 32x terminal multiple (consistent with the deterministic engine), the DCF suggests that the market's current implied growth rate of 9.7% is significantly below Insulet's historical and projected trajectory. We trust the lower Forward P/E target of $284 as it provides a greater margin of safety against potential H2 2026 competitive entries.
We are assuming Insulet successfully captures a meaningful share of the insulin-dependent Type 2 diabetes market by 2028. Recent record customer starts and Insulet’s status as the most prescribed AID (Automated Insulin Delivery) system suggest that the ease of a tubeless design is effectively converting users who previously avoided traditional, complex pumps.
We are assuming gross margins remain stable or expand toward 72% as global manufacturing scales. The company achieved 71% gross margins in the most recent year, and the transition to high-volume automated production lines should help offset any initial pricing pressure from competitors or reimbursement changes in international markets.
The biggest risk is the potential for new tubeless competitors to launch in late 2026, ending Insulet's current monopoly on the form factor. This would likely compress the forward multiple from 35x to 22x, knocking roughly $105 off the per-share fair value as the market adjusts to a pricing-war environment. Watch for FDA clearance news from Medtronic's tubeless division or Tandem's "Sigi" pump throughout the second half of 2026.
Bear case ($162): Medtronic or Tandem successfully launch tubeless competitors in H2 2026, slowing Insulet's new customer starts by 20%; or Type 2 diabetes adoption plateaus as physicians favor GLP-1 weight-loss medications over early insulin initiation.
Bull case ($405): International revenue growth accelerates above 45% following the Omnipod 6 launch and expansion into new Asian markets; or Insulet secures a major partnership for its "Drug Delivery" segment, adding a new recurring revenue stream outside of insulin.
Clearthesis wrote this report from 36 sources, including SEC filings, industry research, and recent news.
How did you like this thesis?
Your feedback helps us make reports better for you
© 2026 Clearthesis.ai · Report generated on June 23, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.
The market is leaning bullish because the shift from traditional injections to wearable patch pumps is rapidly capturing a massive new population of type 2 diabetes patients. Insulet’s Omnipod 5 system is the dominant choice for users seeking simplicity over restrictive, tubed alternatives. By constantly expanding sensor compatibility and upgrading its algorithm, the company maintains a strong competitive edge in a growing market.
Skeptics think that relying on a premium, disposable hardware model leaves the company vulnerable to product quality issues and intense pricing pressure. Frequent product recalls and ongoing legal disputes over technology ownership create uncertainty about whether the company can maintain its high growth rates while defending its patents against cheaper, alternative devices.